Voltar
Artigo Revisado por pares
BIBTEX RIS

Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel–FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice

2012; Springer Science+Business Media; Volume: 134; Issue: 3 Linguagem: Inglês

10.1007/s10549-012-2149-7

ISSN

1573-7217

Autores

Sònia Pernas, Miguel Gil‐Gil, María Ochoa de Olza, Anna Gumà, Fina Climent, Anna Petit, María Jesús, Amparo Garcı́a-Tejedor, Ana López-Ojeda, Cati Falo, Adela Fernandez-Otega, Carlos Mesía, Francisco Javier Pérez-Martin, Ander Urruticoechea, Josep R. Germà,

Tópico(s)

Monoclonal and Polyclonal Antibodies Research

Referência(s)